Intellia Therapeutics, a biopharmaceutical company specializing in CRISPR gene editing, announced its participation in three upcoming investor conferences: Bank of America Securities Health Care Conference on May 12, RBC Capital Markets Global Healthcare Conference on May 20, and Jefferies Global Healthcare Conference on June 3, 2026. The company's management will engage in fireside chats at these events, which will be webcast live and available for replay. This participation highlights Intellia's ongoing efforts to engage with investors and showcase its advancements in gene editing technology and clinical development.
At Google Next 2026, Google Cloud Security used Instruqt's hands-on platform to train over 150 practitioners on Agentic AI capabilities. Participants built their own AI agents in dedicated Google Cloud Vertex AI environments, gaining practical experi...
Ethereum co-founder Vitalik Buterin announced that his influence over the Ethereum Foundation will continue to decrease as the organization restructures to operate more sustainably and with less central control. The Foundation is expanding its board ...
Vitalik Buterin announced that the Ethereum Foundation will reduce its ETH sales and decrease his own influence within the organization to emphasize decentralization and long-term sustainability. The Foundation now holds only 0.16% of all ETH, signal...
The ERShares Private-Public Crossover ETF (XOVR) trades down 5% year-to-date near $19.08, despite strong gains in its public AI mega-cap holdings like Alphabet and NVIDIA. This divergence stems from its unique mix of late-stage private growth assets,...
Private credit defaults in the U.S. have reached record highs, with Fitch reporting a 6.0% default rate in April 2026. This rise is driven by elevated interest rates making refinancing difficult, exposing weaknesses in an industry built on cheap mone...
